The dollars were small but the trend was mighty. Such was the consensus of analysts on the first full quarter results for Acadia Pharmaceuticals Inc. following the launch of Nuplazid (pimavanserin) on May 31 to treat hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Read More
Messenger RNA (mRNA) drug developer Curevac AG added $29.5 million in new funds to its coffers from German investors looking to support the Tübingen-based home team in a hot field defined by sizable early investments. Read More
COLOGNE, Germany – Alignment and differentiation emerged as the two key requirements for successful partnerships during a panel discussion on the transformational deals that shaped the biopharma industry during 2016, here at BIO-Europe on Tuesday. Read More
HONG KONG – The bacterial metabolite prodigiosin and its analogue, obatoclax, have been shown to have therapeutic activity in advanced breast cancer, providing the rationale for clinical trials, Chinese researchers reported in the Oct. 31, 2016, online edition of Proceedings of the National Academy of Sciences. Read More
The FDA finalized a 2010 guidance on using noninferiority trials to establish the effectiveness of new drugs and biologics. Published in Tuesday's Federal Register, the guidance advises on when noninferiority studies can provide interpretable results, how to choose the noninferiority margin and how to test the hypothesis. Read More
Santhera Pharmaceuticals AG, of Liestal, Switzerland, said the Swiss Agency for Therapeutic Products accepted for review the firm's marketing authorization application for Raxone (idebenone) for the treatment of Duchenne muscular dystrophy in patients with respiratory function decline not taking concomitant glucocorticoids. Read More
Imago Biosciences Inc., of San Carlos, Calif., said the first patients were dosed in a phase I/II trial of IMG-7289 for the treatment of high-risk acute myeloid leukemia and high-risk myelodysplastic syndrome. Read More
